BioAlliance undeterred by move to shelve trial

France's BioAlliance Pharma says it's full steam ahead for its strategy to acquire complementary products for oncology and HIV, despite Immtech's decision to end a trial for pafuramidine--a program BioAlliance is partnered on. Immtech announced late Friday that it is shelving a safety study of pafuramidine after seeing reports of liver and kidney abnormalities. The drug was being tested for pneumonia in HIV patients and for African sleeping sickness.

- here's the release
- read the AFX report

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."